APA (7th ed.) Citation

Guchelaar, N. A., Mathijssen, R. H., Boer, M. d., Bekkum, M. L. v., Heijns, J. B., Vriens, B. E., . . . Bos, M. E. Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): A single-arm, multicentre, phase 2 trialResearch in context. Elsevier.

Chicago Style (17th ed.) Citation

Guchelaar, Niels A.D., et al. Trifluridine-tipiracil in Previously Treated Patients with Oestrogen Receptor-positive, HER2-negative Metastatic Breast Cancer (BOOG 2019-01 TIBET Trial): A Single-arm, Multicentre, Phase 2 TrialResearch in Context. Elsevier.

MLA (9th ed.) Citation

Guchelaar, Niels A.D., et al. Trifluridine-tipiracil in Previously Treated Patients with Oestrogen Receptor-positive, HER2-negative Metastatic Breast Cancer (BOOG 2019-01 TIBET Trial): A Single-arm, Multicentre, Phase 2 TrialResearch in Context. Elsevier.